JPWO2020163353A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020163353A5
JPWO2020163353A5 JP2021545713A JP2021545713A JPWO2020163353A5 JP WO2020163353 A5 JPWO2020163353 A5 JP WO2020163353A5 JP 2021545713 A JP2021545713 A JP 2021545713A JP 2021545713 A JP2021545713 A JP 2021545713A JP WO2020163353 A5 JPWO2020163353 A5 JP WO2020163353A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
seq
opening
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021545713A
Other languages
English (en)
Japanese (ja)
Other versions
JP7709917B2 (ja
JP2022519293A (ja
JP2022519293A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/016606 external-priority patent/WO2020163353A1/en
Publication of JP2022519293A publication Critical patent/JP2022519293A/ja
Publication of JPWO2020163353A5 publication Critical patent/JPWO2020163353A5/ja
Publication of JP2022519293A5 publication Critical patent/JP2022519293A5/ja
Priority to JP2025036066A priority Critical patent/JP2025090679A/ja
Application granted granted Critical
Publication of JP7709917B2 publication Critical patent/JP7709917B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021545713A 2019-02-04 2020-02-04 コネキシン４３抗体およびその使用 Active JP7709917B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025036066A JP2025090679A (ja) 2019-02-04 2025-03-07 コネキシン４３抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800869P 2019-02-04 2019-02-04
US62/800,869 2019-02-04
PCT/US2020/016606 WO2020163353A1 (en) 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025036066A Division JP2025090679A (ja) 2019-02-04 2025-03-07 コネキシン４３抗体およびその使用

Publications (4)

Publication Number Publication Date
JP2022519293A JP2022519293A (ja) 2022-03-22
JPWO2020163353A5 true JPWO2020163353A5 (https=) 2023-02-13
JP2022519293A5 JP2022519293A5 (https=) 2023-02-13
JP7709917B2 JP7709917B2 (ja) 2025-07-17

Family

ID=71947290

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021545713A Active JP7709917B2 (ja) 2019-02-04 2020-02-04 コネキシン４３抗体およびその使用
JP2025036066A Pending JP2025090679A (ja) 2019-02-04 2025-03-07 コネキシン４３抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025036066A Pending JP2025090679A (ja) 2019-02-04 2025-03-07 コネキシン４３抗体およびその使用

Country Status (9)

Country Link
US (2) US12187794B2 (https=)
EP (1) EP3920969A4 (https=)
JP (2) JP7709917B2 (https=)
KR (1) KR20210153039A (https=)
CN (2) CN119700967A (https=)
AU (3) AU2020219112A1 (https=)
CA (1) CA3128987A1 (https=)
IL (2) IL320816A (https=)
WO (1) WO2020163353A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095897A1 (en) 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
WO2025006774A1 (en) * 2023-06-30 2025-01-02 Alamab Therapeutics, Inc. Method of treating osteoarthritis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
JP4063769B2 (ja) * 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
US6745478B2 (en) 2002-07-18 2004-06-08 Delillo Dominick D. Multi-purpose work knife
NZ547157A (en) * 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
KR102073629B1 (ko) * 2005-02-03 2020-02-05 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
MX2010012324A (es) * 2008-05-15 2011-01-14 Biogen Idec Inc Anticuerpos anti-fn14 y usos de los mismos.
US20110223204A1 (en) * 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
CA2823154A1 (en) * 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
CN114621346B (zh) * 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
CN107109410B (zh) * 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017147561A1 (en) * 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
CA3095897A1 (en) * 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations

Similar Documents

Publication Publication Date Title
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
RU2376316C2 (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2021520393A5 (https=)
JP5918275B2 (ja) 変形性関節症及び疼痛の治療
JP2020537644A5 (https=)
RU2362780C2 (ru) Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний
JP2019527543A5 (https=)
JP2015523962A5 (https=)
JP2019523295A5 (https=)
JP2018510617A5 (https=)
RU2014105496A (ru) Способы снижения числа эозинофилов
RU2009149294A (ru) Антиген-связывающие белки, нацеленные на orf0657n s.aureus
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
JP2022513420A5 (https=)
RU2010119521A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2019527194A5 (https=)
JP2011509245A5 (https=)
KR102627471B1 (ko) 조작된 항-il-2 항체
JP2017500018A5 (https=)
JP2019505527A5 (https=)
JP2018529661A5 (https=)
EP2970447A1 (en) Pan-elr+ cxc chemokine antibodies
JPWO2020059847A5 (https=)
CN118974091A (zh) T细胞结合蛋白
JPWO2020018922A5 (https=)